GSK 2321138A

Drug Profile

GSK 2321138A

Alternative Names: a-RIX-Tetra; FLU D-QIV; Fluarix Quadrivalent; Fluarix Tetra; Fluarix Tetra 2013/2014; FluarixTetra; GSK-2321138A; IIV4 - GlaxoSmithKline; Inactivated quadrivalent influenza vaccine - GlaxoSmithKline; Influsplit Tetra; Influsplit Tetra 2013/2014; Quadrivalent influenza vaccine – GlaxoSmithKline

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 06 Mar 2018 Efficacy data from a phase III trial in Influenza virus infections released by GlaxoSmithKline
  • 15 Feb 2018 Launched for Influenza virus infections (Combination therapy, In the elderly, Prevention, In adults) in Austria, Czech Republic, Germany, Greece, Italy, Luxembourg, Slovakia, Spain, United Kingdom, Switzerland, France, Belgium (IM)
  • 15 Feb 2018 Launched for Influenza virus infections (In infants, Prevention) in Belgium, Czech Republic, France, Germany, Greece, Italy, Luxembourg, Slovakia, United Kingdom, Spain, Austria, Switzerland (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top